Rapport Therapeutics, Inc. (RAPP)
NASDAQ:RAPP
Want to see RAPP full AI Analyst Report?
RAPP Stock Chart & Stats
$39.71
-$0.34(-1.94%)
At close: 4:00 PM EST
$39.71
-$0.34(-1.94%)
Day’s Range― - ―
52-Week Range$10.51 - $42.27
Previous CloseN/A
Volume10.11K
Average Volume (3M)323.28K
Market Cap
$1.84B
Enterprise Value$1.37B
Total Cash (Recent Filing)$476.78M
Total Debt (Recent Filing)$10.80M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Aug 06, 2026EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding47,826,927
10 Day Avg. Volume322,094
30 Day Avg. Volume323,281
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-16.18
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue68.72
Enterprise Value/Gross Profit70.45
Enterprise Value/Ebitda-11.63
Forecast
1Y Price Target
$55.71Price Target Upside40.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.36
Revenue Forecast (FY)$20.00M
Bulls Say, Bears Say
Bulls Say
Low Leverage, Strong Equity BaseA very low debt-to-equity (~0.02) and sizable equity cushion provide durable financial flexibility to fund clinical programs, absorb setbacks, and negotiate partnerships without immediate solvency pressure. This capital structure reduces refinancing risk over the next several quarters.
Robust Phase 2a RAP-219 DataFollow-up Phase 2a results showing sustained, large seizure reductions and a long (~22-day) half-life materially strengthen RAP-219's clinical profile, supporting a clear pathway to pivotal Phase 3 planning and broader indications. This durable clinical differentiation improves development probability and partnership leverage.
Emerging Revenue InflectionRecording $20M TTM revenue after prior nil results represents a structural change in operations, indicating early commercialization, licensing, or milestone receipts. If sustained, this revenue reduces reliance on pure financing and can help moderate burn as programs scale over the coming quarters.
Bears Say
High Cash Burn And Negative FCFConsistently negative operating and free cash flow (roughly -$80M TTM) reflect a structural financing need to support late-stage development. Continued elevated burn increases dilution risk or forces asset sales/partnerships, constraining strategic optionality over the next several quarters.
Large, Persistent Net LossesA sizeable TTM net loss (~$107M) driven by R&D and operating costs means profitability remains distant. This persistent negative earnings profile limits internal funding capacity and makes long-term planning dependent on successful trial outcomes and external capital or partner support.
Clinical-stage, Limited Commercial ScaleAs a clinical-stage biotech with no marketed products and ~69 employees, the company’s prospects hinge on trial success and regulatory outcomes. This concentration creates binary program risk and limited diversification, leaving the firm exposed to single-program setbacks and partner dependency.
Rapport Therapeutics, Inc. News
RAPP FAQ
What was Rapport Therapeutics, Inc.’s price range in the past 12 months?
Rapport Therapeutics, Inc. lowest stock price was $10.51 and its highest was $42.27 in the past 12 months.
What is Rapport Therapeutics, Inc.’s market cap?
Rapport Therapeutics, Inc.’s market cap is $1.84B.
When is Rapport Therapeutics, Inc.’s upcoming earnings report date?
Rapport Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 51 days.
How were Rapport Therapeutics, Inc.’s earnings last quarter?
Rapport Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.42 earnings per share for the quarter, beating the consensus estimate of -$0.605 by $0.185.
Is Rapport Therapeutics, Inc. overvalued?
According to Wall Street analysts Rapport Therapeutics, Inc.’s price is currently Undervalued.
Does Rapport Therapeutics, Inc. pay dividends?
Rapport Therapeutics, Inc. does not currently pay dividends.
What is Rapport Therapeutics, Inc.’s EPS estimate?
Rapport Therapeutics, Inc.’s EPS estimate is -0.9.
How many shares outstanding does Rapport Therapeutics, Inc. have?
Rapport Therapeutics, Inc. has 47,826,927 shares outstanding.
What happened to Rapport Therapeutics, Inc.’s price movement after its last earnings report?
Rapport Therapeutics, Inc. reported an EPS of -$0.42 in its last earnings report, beating expectations of -$0.605. Following the earnings report the stock price went up 7.744%.
Which hedge fund is a major shareholder of Rapport Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RAPP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rapport Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.71 (40.30% Upside)
$55.71 (40.30% Upside)
Blogger Sentiment
Bullish
RAPP Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
244.70%
12-Months-Change
Fundamentals
Return on Equity
-24.79%
Trailing 12-Months
Asset Growth
64.74%
Trailing 12-Months
Company Description
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
RAPP Stock 12 Month Forecast
Average Price Target
$55.71
▲(40.30% Upside)
Technical Analysis
Ownership Overview
22.59% Insiders
24.53% Mutual Funds
31.89% Other Institutional Investors
13.14% Public Companies and
Individual Investors